Is Endo Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Endo Inc (NDOI) is currently classified as NOT HALAL as of March 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Endo Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Endo Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Endo Inc?

Muslim investors may consider investing in Endo Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Endo Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Endo Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Endo Inc updated?

The Shariah compliance status of Endo Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Endo Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Endo Inc?

You can check the latest Shariah compliance status of Endo Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NDOI Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 24, 2025

Report Source: 2024 Annual Report

Endo Inc. Stock Analysis NDOI

United States Health Care Small Cap Report: 2024 Annual

Endo, Inc. is a pharmaceutical company, which boldly transforming insights into life-enhancing therapies. The company is headquartered in Malvern, Pennsylvania and currently employs 3,116 full-time employees. The company went IPO on 2024-06-27. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The Branded Pharmaceuticals segment includes a variety of branded products in the therapeutic areas of urology, orthopedics, endocrinology and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, AVEED, PERCOCET, TESTOPEL, and EDEX. The Sterile Injectables segment consists primarily of branded sterile injectable products, such as ADRENALIN, VASOSTRICT, APLISOL and certain generic sterile injectable products. The Generic Pharmaceuticals segment consists of solid oral extended-release products and solid oral immediate-release products. The International Pharmaceuticals segment includes a variety of specialty pharmaceutical products, including over-the-counter (OTC) products, sold outside the United States.

Key Statistics of Endo Inc (NDOI)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$23.50$23.59

Today's Open

$23.54

Volume

537.00

P/E Ratio (TTM)

0.32

52 Week Range

$19.85$31.40

Market Cap

1.80B

Avg. Volume

426.50

Dividend Yield

Financial Metrics & Statements of Endo Inc (NDOI)

FAQ's for Endo Inc (NDOI)

According to Musaffa’s Shariah screening methodology, Endo Inc (NDOI) is currently classified as NOT HALAL as of March 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.